Mass Balance Studies, with a Focus on Anticancer Drugs
- 1 January 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 45 (1), 33-58
- https://doi.org/10.2165/00003088-200645010-00003
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Current perspectives of 14 C-isotope measurement in biomedical accelerator mass spectrometryAnalytical and Bioanalytical Chemistry, 2004
- Big physics, small doses: the use of AMS and PET in human microdosing of development drugsNature Reviews Drug Discovery, 2003
- A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil™ (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the ratJournal of Pharmaceutical and Biomedical Analysis, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of Ifosfamide and its MetabolitesClinical Pharmacokinetics, 2001
- Clinical and Preclinical Pharmacokinetics of RaltitrexedClinical Pharmacokinetics, 2000
- Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atomRapid Communications in Mass Spectrometry, 1999
- Renal excretion of iodine-131 labelledmeta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Oral administration of [3H]navelbine in patientsAnti-Cancer Drugs, 1991
- Pharmacokinetic Equivalence of Stable—Isotope‐Labeled and Unlabeled Drugs. Phenobarbital in ManThe Journal of Clinical Pharmacology, 1982
- Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant diseaseEuropean Journal of Cancer (1965), 1978